Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 4/20 | 0.70 |
| ▸ | HTT | P42858 | 5/20 | 0.62 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29472100 | 0.86 | NCF1 (0.76) | NCF1HTTALDH1A1NPSR1SLC22A12 | |
| SCHEMBL22715673 | 0.86 | NCF1 (0.76) | NCF1HTTALDH1A1NPSR1SLC22A12 | |
| SCHEMBL731691 | 0.85 | NCF1 (0.74) | NCF1HTTALDH1A1NPSR1SLC22A12 | |
| SCHEMBL24151230 | 0.84 | ADRB2 (0.58) | NCF1HTTMAPKAPK2MEN1KMT2A | |
| SCHEMBL30734145 | 0.83 | NCF1 (0.67) | NCF1HTTMAPKAPK2MEN1KMT2A | |
| SCHEMBL1543989 | 0.82 | NCF1 (0.70) | NCF1HTTMAPKAPK2ALDH1A1ADRB2 | |
| SCHEMBL3849006 | 0.82 | NCF1 (1.00) | NCF1HTTHTR1AHTR1DHTR1B | |
| SCHEMBL12928129 | 0.82 | NCF1 (0.48) | NCF1HTTMAPKAPK2MEN1KMT2A | |
| SCHEMBL3947682 | 0.82 | KDM4E (0.51) | NCF1HTTMAPKAPK2MEN1KMT2A | |
| SCHEMBL13827009 | 0.82 | NCF1 (0.48) | NCF1HTTMAPKAPK2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-4167982-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2021262596-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021262596-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2018-02-15 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| WO-2014151147-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE, LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-02-07 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012116237-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2012-08-30 | — | — | WO | disclosed |
| EP-2048142-A2 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| EP-1382603-B1 | NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-7074801-B1 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | EISAI CO., LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | NCF1 1581/4885HTT 683/4885MAPKAPK2 132/4885 |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | NCF1 374/4885HTT 2757/4885MAPKAPK2 1013/4885 |
| US-20130035324-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | NCF1 1581/4885HTT 683/4885MAPKAPK2 132/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | NCF1 374/4885HTT 2757/4885MAPKAPK2 1013/4885 |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | NCF1 1581/4885HTT 683/4885MAPKAPK2 132/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | NCF1 1470/4885HTT 985/4885MAPKAPK2 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.